KLK3 and prostate carcinoma: Observational studies[10, 11, 26] found no increase in aggressive or any prostate cancer in testosterone-treated men but their conclusions were limited by the absence of an appropriate comparison group, lack of adjustment for PSA screening and lack of cumulative dosage analyses.